

CLAIMS

1. A composition for oral administration comprising
capsaicinoids in combination with a formulation
base which is acceptable for oral administration,
said formulation base comprising an oil and a
lipophilic additive which is solid or pasty at
room temperature and which amounts to 5 to 20% by
weight, preferably 8 to 15% by weight, of the
composition.
2. A composition as claimed in claim 1, characterized
in that the lipophilic additive is selected from
among waxes, fatty acid mono-, di- or
triglycerides, fatty acids and polyethylene
glycols and the fatty acid polyethylene glycol
esters, as well as their mixtures.
3. A composition as claimed in any of claims 1 to 2,
characterized in that the lipophilic additive is a
mixture of beeswax and glycerol palmitostearate.
4. A composition as claimed in claim 3, characterized
in that the weight ratio between the beeswax and
the glycerol palmitostearate is approximately 1.
5. A composition as claimed in any of claims 1 to 4,
characterized in that the capsaicinoids are
present in the composition in the form of capsicum
resin.
6. A composition as claimed in any of claims 1 to 5,
characterized in that the capsaicinoids represent
0.02 to 5% by weight, preferably 0.1 to 2% by
weight, of the composition.
7. A composition as claimed in any of claims 1 to 6,
characterized in that the oil is selected from

among vegetable oils, such as soya oil, sunflower oil, corn oil, olive oil or nut oil and mineral oils such as liquid paraffin, as well as their mixtures.

5

8. A composition as claimed in any of claims 1 to 7, characterized in that it comprises furthermore one or more physiologically active components other than the capsaicinoids.

10

9. A composition as claimed in claim 8, characterized in that the other physiologically active component(s) amount to 10 to 30% by weight of the composition.

15

10. A composition as claimed in claim 8 or 9, characterized in that at least one among the other physiologically active components is a plant or a plant extract selected from among green tea, the alga *Ascophyllum nodosum*, mate tea, guarana, ephedra or citrus aurantium, as well as their mixtures.

20

11. A composition as claimed in any of claims 8 to 10, characterized in that at least one among the other physiologically active components is a sunflower oil which is rich in conjugated linoleic acid.

25

12. A composition as claimed in any of claims 1 to 11, characterized in that it is presented in a form which is solid or pasty at room temperature.

30

13. A composition as claimed in any of claims 1 to 12, characterized in that it is in the form of soft or hard capsules.

35

14. A composition as claimed in any of claims 1 to 13, characterized in that it is presented in the form

of a soft capsule comprising:

- 15 mg capsicum oleoresin,
- 150 mg green tea extract,
- 75 mg sunflower oil which is rich in conjugated
- 5 linoleic acid,
- 200 mg soya oil,
- 16 mg soya lecithin,
- 29 mg yellow beeswax, and
- 25 mg glycerol palmitostearate,

10 or else

- 15 mg capsicum oleoresin,
- 150 mg Ascophyllum nodosum powder,
- 75 mg sunflower oil which is rich in conjugated
- 15 linoleic acid,
- 200 mg soya oil,
- 16 mg soya lecithin,
- 29 mg yellow beeswax, and
- 25 mg glycerol palmitostearate.

20 **15.** The use of the composition as claimed in any of
claims 1 to 14 as foodstuff, food supplement or
dietetic product.

25 **16.** The use as claimed in claim 15 for stimulating
thermogenesis without exerting an irritant effect
on the gastric mucosa.

30 **17.** The use as claimed in claim 16 for additionally
reducing the appetite.

18. The use as claimed in any of claims 15 to 17 for
reducing or preventing the appearance of cellulite
or reducing or preventing excess weight.

35 **19.** A medicament comprising the composition as claimed
in any of claims 1 to 14.

20. A medicament as claimed in claim 19 intended for

stimulating thermogenesis without irritating effect on the gastric mucosa.

21. A medicament as claimed in claim 20, furthermore intended for reducing the appetite.

5

22. A medicament as claimed in any of claims 19 to 21, intended for the treatment or prevention of obesity, digestive problems such as flatulence, gastric ulcers, gastroesophageal reflux, intestinal infections and circulation problems, in particular hypercholesterolemia.

10